» Articles » PMID: 8807204

Serological Responses to Human Papillomavirus Type 6 and 16 Virus-like Particles in Patients with Cervical Neoplastic Lesions

Overview
Date 1996 Jul 1
PMID 8807204
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Serum samples from 36 cervical carcinoma patients, 33 patients with high-grade squamous intraepithelial lesions, and 31 cytologically normal women were tested by enzyme-linked immunosorbent assay (ELISA) using human papilloma virus type 6 (HPV 6) and HPV 16 virus-like particles as antigens. Forty serum specimens from 1-year-old children were used to assign cutoff points. When serum samples from the subjects infected with HPV 16 were tested in an HPV 16 ELISA detecting immunoglobulin A (IgA), IgG, and IgM binding, 61% showed IgA, 44% showed IgG, and 39% showed IgM reactivity. Of HPV 6- or 11- or HPV 18-infected subjects. fewer than 17% showed IgA or IgG responses and 33% showed IgM reactivity. In contrast, 13% showed IgA, 10% showed IgG, and 16% showed IgM reactivity in the HPV DNA-negative controls. The results suggest that the IgA and IgG responses are HPV 16 specific and the IgM response is cross-reactive to different HPV types. On the other hand, the serological responses to HPV 6 did not differ in the patient and control groups. The percentages of patients positive for both IgA and IgG antibodies were significantly higher in the groups with high-grade squamous intraepithelial lesions (12% [4 of 33]; P = 0.04) and cancer (17% [6 of 36]; P = 0.02) than in the healty women (0% [0 of 31]), and the percentages for either IgA or IgG were higher for the cancer group (47% [17 of 36]; P = 0.01) than in the normal group (19% [6 of 31]). Most sera positive for IgA and IgG in the patient groups showed higher titers than those in the normal group. All these results suggest that high IgA and IgG responses are good indicators for estimating HPV 16 infection.

Citing Articles

Immunodiagnosis and Immunotherapeutics Based on Human Papillomavirus for HPV-Induced Cancers.

Dong Z, Hu R, Du Y, Tan L, Li L, Du J Front Immunol. 2021; 11:586796.

PMID: 33488587 PMC: 7820759. DOI: 10.3389/fimmu.2020.586796.


A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.

Monroy-Garcia A, Gomez-Lim M, Weiss-Steider B, la Rosa G, Hernandez-Montes J, Perez-Saldana K Virol J. 2011; 8:59.

PMID: 21306638 PMC: 3042957. DOI: 10.1186/1743-422X-8-59.


Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women.

Nakagawa M, Viscidi R, Deshmukh I, Da Costa M, Palefsky J, Farhat S Clin Diagn Lab Immunol. 2002; 9(4):877-82.

PMID: 12093689 PMC: 120038. DOI: 10.1128/cdli.9.4.877-882.2002.

References
1.
Sasagawa T, Inoue M, TANIZAWA O, Yutsudo M, HAKURA A . Identification of antibodies against human papillomavirus type 16 E6 and E7 proteins in sera of patients with cervical neoplasias. Jpn J Cancer Res. 1992; 83(7):705-13. PMC: 5918929. DOI: 10.1111/j.1349-7006.1992.tb01970.x. View

2.
Hagensee M, Carter J, Wipf G, Galloway D . Immunization of mice with HPV vaccinia virus recombinants generates serum IgG, IgM, and mucosal IgA antibodies. Virology. 1995; 206(1):174-82. DOI: 10.1016/s0042-6822(95)80032-8. View

3.
Hording U, Iversen A, Sebbelov A, Bock J, Norrild B . Prevalence of human papillomavirus types 11, 16 and 18 in cervical swabs. A study of 1362 pregnant women. Eur J Obstet Gynecol Reprod Biol. 1990; 35(2-3):191-8. DOI: 10.1016/0028-2243(90)90161-s. View

4.
Nonnenmacher B, Hubbert N, Kirnbauer R, Shah K, Munoz N, Bosch F . Serologic response to human papillomavirus type 16 (HPV-16) virus-like particles in HPV-16 DNA-positive invasive cervical cancer and cervical intraepithelial neoplasia grade III patients and controls from Colombia and Spain. J Infect Dis. 1995; 172(1):19-24. DOI: 10.1093/infdis/172.1.19. View

5.
Ghim S, Christensen N, KREIDER J, Jenson A . Comparison of neutralization of BPV-1 infection of C127 cells and bovine fetal skin xenografts. Int J Cancer. 1991; 49(2):285-9. DOI: 10.1002/ijc.2910490224. View